Home > Insider Trading > Filing (0001104659-22-049930)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1635088	Roivant Sciences Ltd.	ROIV	Pharmaceutical Preparations (2834)	981173944

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1636684	Ltd. Holdings Dexxon	1 Dexcel Street Or Akiva L3 3060000	No	No	Yes	No
1636701	Dan Oren	1 Dexcel Street Or Akiva L3 3060000	No	No	Yes	No
1720007	Ltd. Technologies Pharma Dexcel	21 Nahum Haftzadi Street Jerusalem L3 9548402	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2022-04-22	31,685	$3.83	98,840,843	No	4	P	Direct
Common Shares	Acquisiton	2022-04-25	8,600	$3.91	98,849,443	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Footnotes

Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.
The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.685 to $3.88.
The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.825 to $3.99.
The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.